REGULATORY
MSD’s Antifungal Drug Noxafil in for Price Cuts as Chuikyo OKs CEA Results
Japan’s all-important reimbursement policy panel on November 10 approved the results of cost-effectiveness assessments (CEAs) for MSD’s antifungal agent Noxafil (posaconazole), putting it in line for a downward price adjustment. Under the CEA scheme, which was introduced for post-launch price…
To read the full story
Related Article
- MSD’s Noxafil Price to Be Trimmed 0.5% under CEA Scheme
November 17, 2021
REGULATORY
- Govt to Explore Greater Rewards for Innovative Drugs in Honebuto
June 29, 2026
- MHLW Starts Technical Review of OTC-Like Drug Charge Exemptions
June 29, 2026
- Takeda to Shift Immunoglobulin Production to 10% Formulation
June 29, 2026
- Japan’s Immunoglobulin Self-Sufficiency Rate Falls Below 60%
June 29, 2026
- MOF Panel Renews Push for Full-Scale Off-Year Revision in FY2027
June 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





